

[Click here to view linked References](#)

Short-term outcomes after elective colon cancer surgery: An observational study from the Norwegian registry for gastrointestinal and HPB surgery, NoRGast.

LS Nymo, S Norderval, MT Eriksen, HH Wasmuth, H Kørner, BA Bjørnbeth, T Moger, A Viste, K Lassen

LS Nymo	MD ^{1,2}
S Norderval	MD, PhD, Professor of Surgery ^{1,2}
MT Eriksen	MD, PhD, Head of Division, Associate Professor ^{3,4}
HH Wasmuth	MD, PhD ⁶
H Kørner	MD, PhD, Professor of Surgery ^{7,8}
BA Bjørnbeth	MD, PhD ^{4,5}
T Moger	MD ⁹
A Viste	MD, PhD, Professor of Surgery ^{8,10}
K Lassen	MD, PhD, Professor of Surgery ^{2,5}

¹ Department of Gastrointestinal Surgery, University Hospital of North Norway, Tromsø, Norway

² Institute of Clinical Medicine, Faculty of Health Science, UIT, the Arctic University of Norway, Tromsø, Norway

³ Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, 0424 Oslo

⁴ Institute of Clinical Medicine, University of Oslo, 0316 Oslo

⁵ Department of HPB Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway

⁶ Department of Gastrointestinal Surgery, St. Olav Hospital, Trondheim University Hospital, 7006 Trondheim, Norway

⁷ Department of Gastrointestinal Surgery, Stavanger University Hospital, 4068 Stavanger, Norway

⁸ Institute of Clinical Medicine, University of Bergen, Norway

⁹ Innlandet Hospital Trust, Surgical Department, Lillehammer, Norway

¹⁰ Haukeland University Hospital, Bergen, Norway

Corresponding author: Linn Såve Nymo **Email address:** linnsnyo@gmail.com

No funding was received

ABSTRACT

Background: To describe the real burden of major complications after elective surgery for colon cancer in Norway, and to assess which predictors that are significantly associated with the short-term outcome.

Methods: An observational, multi-centre analysis of prospectively registered colon resections registered into the Norwegian Registry for Gastrointestinal Surgery, NoRGast, between January 2014 and December 2016. A propensity score-adjusted subgroup analysis for surgical access groups was attempted, with laparoscopic resections grouped as intention-to-treat.

Results: Out of 1812 resections, 14.0% of patients experienced a major complication within 30 days following surgery. The over-all reoperation rate was 8.7%, and rate of reoperation for anastomotic leak was 3.8%. Twenty patients (1.1%) died within 30 days after surgery. Higher age was not a significant predictor of major complications, including 30-day mortality. After correction for all co-variables, open access surgery was associated with higher rates of major complications (OR 1.67 (CI 1.22-2.29), $p=0.002$), higher 30-day mortality (OR 4.39 (CI 1.19-16.13) $p=0.026$) and longer length-of-stay (HR 0.58 (CI 0.52-0.65) $p<0.001$).

Conclusions: Our results indicate a low complication burden and high rate of uneventful patient journeys after elective surgery for colon cancer in Norway. Age was not associated with higher morbidity or mortality rates. Open access surgery was associated with an inferior short-term outcome.

Key words: Short-term outcomes, colon cancer, elective surgery, laparoscopy

INTRODUCTION

1
2
3
4 In 2012 Norway reported the world's 6th highest incidence of colorectal cancer (1), and
5 the incidence has for the past decades been steadily increasing. (2) The prognosis
6 following surgical treatment is excellent, with a 5-year relative survival rate of 84 %
7 after resection for non-metastatic disease. (3) Even the oldest and most frail patients
8 will often be offered surgery with curative intent. While the potential gain from
9 uneventful surgery is large, the consequences of major complications may be
10 devastating with loss of function and impaired quality of life that are at best temporary.
11 There is also a growing interest for the negative impact from non-fatal major surgical
12 complications on long-term cancer survival. (4-6) Given its high incidence rate and
13 potentially good prognosis, a nationwide high-quality surgical service for colon cancer is
14 a vital concern for public health.
15
16
17
18
19
20
21
22
23
24

25
26 While surgery for most other cancer forms (including rectal cancer) is centralized,
27 surgery for malignant tumours of the colon is still performed in general hospitals in
28 Norway. The Norwegian Colorectal Cancer Registry (NCCR) continuously surveys the
29 oncological outcomes on national and hospital level, but includes only limited data for
30 major complications and risk factors. Randomized controlled trials (RCTs) and selected
31 single-centre series should be complemented by data that illustrate real-life outcomes
32 for all patients and all surgeons. The novel Norwegian Registry for Gastrointestinal
33 surgery (NoRGast) is a prospective registry for colorectal, upper gastrointestinal and
34 hepato-pancreato-biliary (HPB) surgery that offers readily available outcome data for a
35 national cohort and includes core case-mix factors for risk adjustment (7). The registry
36 is procedure-based, and all formal HPB or gastrointestinal resections are eligible for
37 inclusion. Data is entered by a health care professional through a secured web portal. All
38 Norwegian hospitals, ranging from large tertiary colorectal, upper GI or HPB units to
39 small general hospitals performing less than 20 colonic resections per year are invited
40 to contribute. Contribution was initially voluntarily, but as the registry received status
41 as a national quality registry in 2016 the registration has since been made mandatory.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

63 Short-term outcomes after surgery for colon cancer
64
65

The aim of this study was to describe the real-life complication burden after elective resections for colonic cancer in Norway, and to assess factors that influence the short-term outcome.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

METHODS

1
2
3
4 NoRGast started data collection in 2014 and holds by entry of 2018 data for over 17.000
5 resections for both malignant and benign disease. The dataset includes patient baseline
6 data, procedural characteristics and outcomes prospectively registered by the operating
7 unit under index admission and at a 30-day follow-up. This is described in more detail
8 elsewhere. (7) ERAS has been endorsed by all hospitals following a series of national
9 symposia. However, this registry does not hold any data that assess the degree of
10 compliance to standard protocols.
11
12
13
14
15
16

17
18 Data from all colonic resections performed between 01.01.2014 and 01.12.2016 were
19 retrieved from the NoRGast database. The included resections were grouped by NCSP-
20 codes (8) as "ileocecal resections and right hemicolectomies" (JFB 20-21-30-31-33-34),
21 "resections of the transverse colon and left hemicolectomies" (JFB 40-41-43-44),
22 "sigmoid resections" (JFB 46-47-53-54-60-61) and "subtotal, total and other
23 colectomies" (JFB 50-51-63-64 and JFH 00-01-10-11). Only resections performed for
24 confirmed or strongly suspected colonic neoplasia were included. These were identified
25 by having a corresponding ICD-diagnosis (9) denoting cancer or neoplasia (C18.0-9, C19,
26 D01.0-1, D12.0-7, D37.2-4 or K63.5). Non-scheduled surgery, defined by start of
27 anaesthesia between 4 PM and 8 AM or performed during weekends and public
28 holidays, was excluded. Tumour stage is not recorded in the registry and was
29 accordingly not included in this analysis.
30
31
32
33
34
35
36
37
38
39
40
41

42 All patients included in NoRGast have given written consent to have their data stored in
43 the registry, and the register holds a data storage licence from the Norwegian Data
44 Authority. The study was approved by both the Regional Ethics Committee and the Data
45 Protection Officer, and performed within the limits and regulations of the written
46 consent already obtained.
47
48
49
50
51
52

53 Severe pulmonary disease ($FEV1 < 50\%$ and or vital capacity $< 60\%$) and severe cardiac
54 disease (NYHA class 3 or 4, or severe arrhythmia requiring mechanical support) were
55 defined in concordance with the modified Estimation of Physiologic Ability and Surgical
56 Stress (mE-PASS) definitions (10). Weight loss was defined as weight loss of any size
57
58
59
60
61

62
63 Short-term outcomes after surgery for colon cancer
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

calculated from patient-reported weight 6 months prior to surgery and scaled weight upon admission. Surgical access modality was analysed as intention-to-treat, comparing all intended laparoscopic resections (completed or converted to open procedure) to primarily open resections. CRP and albumin levels used in the modified Glasgow Prognostic Score (mGPS) were measured within three weeks preoperatively.

The Accordion system for grading postoperative complications is used in the registry.

(11) Briefly, any percutaneous, angiographic or endoscopic intervention is classified as Accordion grade 3, reoperation with new access to the abdomen or single organ failure (SOF) as Accordion grade 4, reoperation *and* SOF, or multi-organ failure (MOF) as Accordion grade 5, and death as Accordion grade 6. (11) Only the highest graded complication is scored for any given patient. The primary outcome was any major complication (defined as Accordion grade 3 or higher) occurring within 30 days after index surgery with separate sub-analyses for reoperation, anastomotic leak (AL) and mortality. All major complications occurring during transfer- or readmission stays within 30 days were also included. AL was defined as reoperation with anastomotic dehiscence as the primary intraoperative finding. Only resections where a new anastomosis was fashioned were included in analysis of AL rates. Deep infection near the anastomosis was classified as AL if discovered upon reoperation, but classified as accordion grade 3 (and omitted from AL definition) if solely percutaneous drainage was performed.

For univariable analyses Pearson chi-square or Fischer exact test (as fit) was used for categorical data, and two-sided t-test was used for continuous variables. Unadjusted odds ratios (OR) were computed for crude effect measure. A backward, step-wise method for binary logistic regression was used to further explore associations between predictors and outcomes, with adjusted OR (aOR) estimated for effect size. Only predictors with a p-value <0.05 in univariable analysis for each outcome were included. To assess the regression model for possible multicollinearity the variance inflation factor was computed. For subgroup analyses comparing outcomes for access modality, a propensity score correcting for skewness in baseline characteristics was calculated. (12) The propensity score was then included in a second binary logistic regression together with access modality, age and gender. Correction with propensity score in logistic

Short-term outcomes after surgery for colon cancer

1 regression was chosen over propensity score matching due to minor baseline
2 differences in the two access groups. Patients with missing values were selectively
3 excluded from the univariate analyses, and for regression analyses patients with any
4 missing value were excluded. Predictors with a level of missing values above 20% were
5 excluded from analyses. Age was grouped for univariable analyses, but analysed as a
6 continuous variable in regression analyses. Significance level was set to $p < 0.05$, and all
7 confidence intervals were 95%. SPSS 24 software (IBM) was used for all analyses.
8
9
10
11
12

13
14 The manuscript was drafted in accordance with the STROBE guidelines for
15 observational studies. (13)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

RESULTS

1
2
3
4 Data from 2778 colon resections performed between 1 January 2014 and 15 December
5 2016 were retrieved from the NoRGast database. Of these, 966 patients were excluded
6 for either having a main diagnosis of non-neoplastic disease (n=711), start of
7 anaesthesia between 4 PM and 8 AM indicating non-scheduled surgery (n=108) or both
8 (n=147), leaving 1812 eligible patients for further analysis. See flowchart (Figure 1). A
9 total of 960 resections (53.0%) were completed by laparoscopic technique, 109
10 resections (10,2% of all commenced as laparoscopy) were converted to open technique,
11 and 743 (41.0%) were primarily open procedures. Sixteen surgical units contributed
12 data, of which five were large academic hospitals and the remaining units general
13 hospitals with a varying annual number of colonic resections. The distribution in use of
14 laparoscopy is grouped by annual hospital volume and shown in Table 1. The
15 contributing hospitals perform approximately 60 % of the annual number of colonic
16 resections in Norway. The median number of included resections from each unit was
17 138 (range 24-365) and the median frequency of laparoscopic access 69.0% (range 28-
18 100). Preoperative weight loss suffered from a high number of missing values (47%)
19 due to lacking registration of patient-reported weight 6 months prior to surgery, and
20 was excluded from further analysis. The rate of missing values was 16.9% for the
21 modified Glasgow Prognostic Score (mGPS), 7.0% for BMI and all other variables had a
22 missing value rate of less than 2%.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 Of the 1812 resected patients, 249 (14.0%) experienced a major complication (Table 2,
42 Figure 2). Of these 249 patients, 20 (1.1%) died (i.e. Accordion grade 6). Another 17
43 patients (0.9%) had a grade 5 complication; 171 patients (9.4%) had grade 4, and 46
44 patients (2.5%) a grade 3 complication. In univariable analysis, older age, male gender,
45 higher ECOG-, mGPS- or ASA-scores and open surgery were all associated with a higher
46 complication rate. In a multivariable model, the higher complication rates observed with
47 higher mGPS (aOR mGPS 0 to 2: 1.82 (CI 1.17-2.82)) and ASA-scores (aOR ASA 1 to 3:
48 2.27 (CI 1.06-4.87)) as well as open access technique (aOR 1.55 (CI 1.15-2.10)) remained
49 statistically significant. The crude incidences of reinterventions and organ failure
50 stratified by access type are shown in Figure 3.

51
52
53
54
55
56
57
58
59
60
61
62
63 Short-term outcomes after surgery for colon cancer
64
65

1 A total of 158 patients (8.7%) had a reoperation within 30 days (Table 3). Of these, 146
2 patients had a reoperation during the index stay and 26 patients following primary
3 discharge, but within 30 days from index surgery. Main finding at reoperation was AL in
4 62 (39.2%) patients, wound dehiscence in 32 (20.3%), intraabdominal bleeding in 11
5 (7.0%) and deep infection not in proximity to the anastomosis in 9 (5.7%) patients. In
6 39 patients (24.7%) there were other findings, and in five patients (3.2%) there were no
7 specific findings upon reoperation. Male gender, open access and resection type were
8 significant single predictors for undergoing a reoperation. In multivariable analysis, only
9 male gender (aOR 1.48 (CI 1.06-2.06)) and resection type remained statistically
10 significant.
11
12
13
14
15
16
17
18
19

20 Some 1663 patients (91.8 %) had a new anastomosis fashioned at index surgery, of
21 whom 62 (3.7%) had a reoperation with AL as primary finding (Table 4). The only
22 significant predictor of AL requiring reoperation was resection type (aOR for AL with
23 ileocecal and right hemicolectomies as reference: transversal and left hemicolectomies
24 2.46 (CI 1.23-4.93) and subtotal, total and other colectomies 2,20 (CI 1.40-8.83)).
25
26
27
28
29
30

31 Twenty patients died within 30 days, yielding an overall 30-day mortality rate of 1.1%
32 (Table 5). Older age, higher WHO-ECOG-, mGPS- or ASA-score, pulmonary comorbidity,
33 cardiac comorbidity and open access were significant predictors in univariable analysis.
34 After multivariable analysis only open access (aOR 2.87 (CI 1.08-7.59)), severe
35 pulmonary disease (aOR 4.95 (CI 1.83- 13.31)) and severe cardiac disease (aOR 2,92 (CI
36 1.09-7.82)) remained statistically significant predictors of death. Fourteen of the 20
37 patients who died did not undergo a reoperation. The mortality rate at 30 days was
38 1.9% (14 out of 743) after open surgery and 0.6% (6 out of 1069) after laparoscopic
39 surgery (p = 0.008).
40
41
42
43
44
45
46
47
48
49

50 Some 177 patients (9.8%) were readmitted within 30 days; either to index hospital
51 (n=160) or another hospital (n=17). The readmission rates among patients who had a
52 anastomosis fashioned during index surgery was 9.6% (160 out of 1664) compared to
53 11.5% (17 out of 148) of those who did not have a new anastomosis. . A total of 26
54 patients had a reoperation during the readmission stay, of whom 7 also had a
55 reoperation during the index stay. The overall LoS was mean 7.4 days and median 5
56
57
58
59
60
61
62
63
64
65

Short-term outcomes after surgery for colon cancer

1 days (IQR 4-8), with median LoS for laparoscopic and open resections of 4 days (IQR 3-
2 6) and 7 days (IQR 5-11), respectively.
3
4

5 At the time of surgery, 452 patients (25.0%) in the cohort were older than 80 years. Of
6 these, 82.5% did not experience any major complication, and 30-day mortality was
7 2.2%. After covariable adjustment, age was not a statistically significant predictor for
8 major complications. A high fraction of patients had a new anastomosis fashioned and
9 this did not differ between age groups. There was a lower rate of AL requiring
10 reoperation (3.1%) observed in the >80 group, but higher age was not associated with
11 lower AL rate (OR 0.98, CI (0.96-1.00) p=0.063).
12
13
14
15
16
17
18
19

20 Open access technique was associated with an inferior outcome when compared to
21 laparoscopic access. Several baseline characteristics differed between the surgical
22 access groups, with a trend indicating that patients operated upon with open technique
23 were somewhat more high-risk than those who underwent a laparoscopic procedure
24 (Table 6). Therefore, we performed a regression analysis of access as a predictor
25 adjusted with a propensity score correcting for baseline differences between the two
26 surgical access groups (Table 7). A difference in disfavour of open technique remained
27 statistically significant for rate of any major complication (aOR 1.67 (CI 1.22-2.29)), 30-
28 day mortality (aOR 4.39 (CI 1.19-16.13)) and LoS (aHR 0.58 (0.52-0.65)).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

DISCUSSION

1
2
3
4 Population-based data for the complication burden and magnitude of impact from risk
5 factors may aid clinicians and patients in decision-making and provide essential
6 backdrops for interpretation of clinical trials. This multi-centre study from both low-
7 and high-volume units throughout Norway reveals a low rate of major complications,
8 with low overall rates of reoperation, anastomotic leak (AL) requiring reoperation and
9 mortality within 30 days.
10
11
12
13
14
15

16 A high proportion (86.0%) of this unselected cohort did not experience any kind of
17 major complication. When compared to other population-based publications our results
18 are in line with reports from the Swedish (8.0 % reoperations, 4.2 % AL and 1.4%
19 mortality) (14), and Danish (4.3% AL and 1.4 % mortality) (15), national colorectal
20 cancer registries. A recent retrospective single-centre study from Sweden reported an
21 AL rate of over 7.0% for colonic resections. (16) Notably, AL rates are not directly
22 comparable due to diverging definitions, as AL rates in NoRGast do not include micro
23 leakages that do not necessitate a reoperation. AL requiring only percutaneous drainage
24 would within our registry be classified as Accordion 3 together with any other
25 endoscopic or percutaneous intervention (including drainage of pleural effusion). Data
26 from a Dutch national report (17) however, corresponds to a rate of reoperations due to
27 AL of 6.4% and an overall mortality rate of 3.4% after elective colonic surgery, which are
28 both somewhat higher than in the current study.
29
30
31
32
33
34
35
36
37
38
39
40
41

42 The overall LoS in our unselected material was short, in line with single centre reports
43 from specialized Enhanced Recovery After Surgery (ERAS) units and fast-track
44 programs, and shorter than several population-based studies. (18-21). The readmission
45 rate of 9,8% is not exceeding readmission rates in reports with longer primary LoS (22,
46 23) and hence seems acceptable, reflecting an overall reasonable discharge policy. The
47 conversion rate of 10.2% of all commenced laparoscopy is in line with recent reports
48 from other unselected cohorts (24, 25).
49
50
51
52
53
54
55
56

57 Age has both traditionally and in recent publications been linked to complicated and
58 prolonged postoperative hospital stays (26), but comparable complication rates and
59
60
61

62
63 Short-term outcomes after surgery for colon cancer
64
65

1 survival after surgical treatment of octogenarians have also been published. (27, 28)
2 This study showed no association between higher age and major complications,
3 including mortality. The tendency of a low rate of AL requiring reoperation among the
4 oldest has been observed in other publications (17). These non-inferior outcomes
5 among the oldest may partly be due to younger patients receiving more extensive
6 surgery. One may further assume that octo- and nonagenarians undergoing surgery
7 have been carefully selected and that the rather crude indicators in the registry have not
8 fully captured their low risk profile. Nevertheless, our results indicate that such a
9 selection results in a comparatively good outcome in those accepted for surgery.
10
11
12
13
14
15
16

17
18 The non-inferior short-term (non-oncological) outcomes after laparoscopic surgery for
19 colon cancer were confirmed in early RCTs (29, 30). A recent Japanese RCT reported
20 lower morbidity after laparoscopy. (31) While several observational studies and long-
21 term follow-ups after RCTs indicate a non-inferior long-term survival (32-34), a large
22 population-based European retrospective study even reported enhanced survival after
23 laparoscopy. (35) A meta-analysis on both short- and long-term outcomes after RCTs
24 suggests that laparoscopy may be preferred due to superior short-term results. (36) A
25 large retrospective report including more than 200.000 patients in the US reported,
26 similar to our study, diverging results for morbidity, mortality, rate of routine discharge
27 and LoS, and concluded with benefits from a laparoscopic approach. (21) Although the
28 guidelines from the Norwegian Gastrointestinal Cancer Group do not clearly recommend
29 either access modality over the other (37), the Norwegian Colorectal Cancer Registry
30 (NCCR) measures laparoscopy rate as a quality indicator. (3, 37) The rate of procedures
31 commenced as laparoscopy in our study (59%) is in line with national cohorts from the
32 NCCR for 2014 (52%) and 2015 (56%). (3)
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47
48 The association between surgical access and diverging outcomes in our data is strong.
49 The over-all rate of major complications was almost twice as high in the open access
50 group, and the distribution in severity of complications did not differ between the access
51 groups (Figure 2). Data on tumour stage are not included in this registry (NoRGast). In a
52 Norwegian national cohort of colon cancer resections from 2007-2010, 11.7% presented
53 as T4-tumours, of which 84.3% were removed by open access. (38). Although the
54 limitations of laparoscopic technique have gradually declined, there is a possibility of a
55
56
57
58
59
60
61
62

63 Short-term outcomes after surgery for colon cancer
64
65

1 higher proportion of large-sized and T4 tumours in the open access group. Tumour size
2 and stage could both affect the choice of access and choice of restoration, and contribute
3 to morbidity and hence represents a possible confounder. There was a lower rate of new
4 anastomosis fashioned in the open surgery group versus the laparoscopy group (95.0%
5 vs 87.2%) in the current cohort, which may partly be due to inter-access differences in
6 resection types performed. There was a larger proportion of sigmoid resections in the
7 laparoscopy group and more transverse, left sided and total/subtotal colectomies done
8 by open access. As these latter subtypes of colonic resections were associated with a
9 higher complication rate, resection type was included in the basis of the propensity
10 score correction. Its skewing effect on outcomes was hence adjusted for but still did not
11 affect the lower complication rate following laparoscopic surgery. Furthermore, the
12 lower rate of primary reconstruction resulted in a lower proportion of patients under
13 risk for AL, and would in theory diminish the risk of major adverse events in the open
14 resection group. Our results must be interpreted with caution due to possible patient
15 selection bias between access modalities not revealed by the case-mix factors registered.
16 However, the observed large inter-unit variation in use of laparoscopy (range 28-100,
17 Table 1) cannot be explained by patient or tumour factors alone, and must to some
18 extent be a result of diverging attitudes between the units regarding the routine use of
19 laparoscopic access .

20 Some limitations need to be addressed. The included resections were registered from 16
21 separate surgical departments throughout Norway, and this material does not constitute
22 a complete national cohort. In 2015 altogether 28 units reported more than 20
23 resections for colonic malignancies to the NCCR (3). The study period included the
24 sparse start of the registry and most units had not been reporting for two full years. The
25 completeness of data on unit level was therefore necessarily variable and impossible to
26 assess. No attempt was hence made to analyse the results on hospital level. Non-
27 scheduled surgery performed within office hours was not possible to identify, and might
28 be a confounder adding additional burden to the open access group. Considering the low
29 complication rates, the variable coverage rate on an institutional level may raise the
30 suspicion of selection bias. Although unlikely, this cannot be completely refuted until
31 more complete cohorts are gathered.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

CONCLUSIONS

Our data indicate low complication rates and a high fraction of uneventful patient journeys after scheduled surgery for colon cancer in Norway when compared to reports from other national registers in countries of similar population. Age was not associated with higher morbidity or mortality rates. Within the limitations of an observational study and in absence of stratification for tumour stage, our data show the use of open access technique to be associated with higher complication rates.

Conflicts of interest:

On behalf of all authors: The authors constitute the board of the NoRGast registry. No other conflicts of interest are declared.

Linn Såve Nymo:	Nothing to disclose
Stig Norderval	Nothing to disclose
Thomas Moger	Nothing to disclose
Morten Tandberg Eriksen	Nothing to disclose
Asgaut Viste	Nothing to disclose
Hans Wasmuth	Nothing to disclose
Bjørn-Atle Bjørnbeth	Nothing to disclose
Kristoffer Lassen	Nothing to disclose

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-86.
2. Cancer registry of Norway: Cancer incidence, mortality, survival and prevalence in Norway: National report 2015. https://www.kreftregisteret.no/globalassets/cancer-in-norway/2015/cin_2015pdf. 2015.
3. Colorectal Cancer registry of Norway: National report 2015. <https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2016/arsrapport-2015-tykk--og-endetarmskreftpdf>. 2016.
4. Aahlin EK, Olsen F, Uleberg B, Jacobsen BK, Lassen K. Major postoperative complications are associated with impaired long-term survival after gastro-esophageal and pancreatic cancer surgery: a complete national cohort study. *BMC Surg*. 2016;16(1):32.
5. Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of Long-Term Survival After Major Surgery and the Adverse Effect of Postoperative Complications. *Transactions of the Meeting of the American Surgical Association*. 2005;123(&NA;):32-48.
6. Pucher PH, Aggarwal R, Qurashi M, Darzi A. Meta-analysis of the effect of postoperative in-hospital morbidity on long-term patient survival. *Br J Surg*. 2014;101(12):1499-508.
7. Lassen K, Nymo LS, Norderval S. The new national registry for gastrointestinal surgery in Norway: NoRGast. *Scandinavian Journal of Surgery* 2017;107(3):7.
8. NOMESCO Classification of Surgical Procedures (NCSP), version 1.15. <http://nordendiva-portal.org/smash/recordjsf?pid=diva2%3A968721>.
9. International statistical classification of diseases and related health problems. 10th revision, edition 2010. <http://apps.who.int/classifications/icd10/browse/2016/en>.
10. Haga Y, Ikejiri K, Wada Y, Takahashi T, Ikenaga M, Akiyama N, et al. A multicenter prospective study of surgical audit systems. *Ann Surg*. 2011;253(1):194-201.
11. Strasberg SM, Linehan DC, Hawkins WG. The accordion severity grading system of surgical complications. *Ann Surg*. 2009;250(2):177-86.
12. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res*. 2011;46(3):399-424.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61(4):344-9.
14. Swedish colorectal cancer registry: National report, 2015. ISBN 91-89048-63-6. 2016.
15. National report from the Danish Colorectal Cancer Group Database 2015. https://dccgdk/wp-content/uploads/2017/10/Aarsrapport_2015pdf.
16. Gessler B, Eriksson O, Angenete E. Diagnosis, treatment, and consequences of anastomotic leakage in colorectal surgery. *Int J Colorectal Dis*. 2017;32(4):549-56.
17. Bakker IS, Grossmann I, Henneman D, Havenga K, Wiggers T. Risk factors for anastomotic leakage and leak-related mortality after colonic cancer surgery in a nationwide audit. *Br J Surg*. 2014;101(4):424-32.
18. Sarin A, Litonius ES, Naidu R, Yost CS, Varma MG, Chen LL. Successful implementation of an Enhanced Recovery After Surgery program shortens length of stay and improves

postoperative pain, and bowel and bladder function after colorectal surgery. *BMC Anesthesiol.* 2016;16(1):55.

19. Lee TG, Kang SB, Kim DW, Hong S, Heo SC, Park KJ. Comparison of early mobilization and diet rehabilitation program with conventional care after laparoscopic colon surgery: a prospective randomized controlled trial. *Diseases of the colon and rectum.* 2011;54(1):21-8.

20. Shum NF, Choi HK, Mak JC, Foo DC, Li WC, Law WL. Randomized clinical trial of chewing gum after laparoscopic colorectal resection. *Br J Surg.* 2016;103(11):1447-52.

21. Juo YY, Hyder O, Haider AH, Camp M, Lidor A, Ahuja N. Is minimally invasive colon resection better than traditional approaches?: First comprehensive national examination with propensity score matching. *JAMA surgery.* 2014;149(2):177-84.

22. Woodfield JC, Jamil W, Sagar PM. Incidence and significance of postoperative complications occurring between discharge and 30 days: a prospective cohort study. *J Surg Res.* 2016;206(1):77-82.

23. Gonzalez-Ayora S, Pastor C, Guadalajara H, Ramirez JM, Royo P, Redondo E, et al. Enhanced recovery care after colorectal surgery in elderly patients. Compliance and outcomes of a multicenter study from the Spanish working group on ERAS. *Int J Colorectal Dis.* 2016;31(9):1625-31.

24. Allaix ME, Furnee EJ, Mistrangelo M, Arezzo A, Morino M. Conversion of laparoscopic colorectal resection for cancer: What is the impact on short-term outcomes and survival? *World J Gastroenterol.* 2016;22(37):8304-13.

25. de Neree Tot Babberich MPM, van Groningen JT, Dekker E, Wiggers T, Wouters M, Bemelman WA, et al. Laparoscopic conversion in colorectal cancer surgery; is there any improvement over time at a population level? *Surg Endosc.* 2018;32(7):3234-46.

26. Jafari MD, Jafari F, Halabi WJ, Nguyen VQ, Pigazzi A, Carmichael JC, et al. Colorectal Cancer Resections in the Aging US Population: A Trend Toward Decreasing Rates and Improved Outcomes. *JAMA surgery.* 2014;149(6):557-64.

27. Yang L, Ma Q, Yu YY, Wang C, Meng WJ, Adell G, et al. Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article. *Medicine.* 2014;93(28):e266.

28. Fujii S IA, Ota M, Yamagishi S et al. Short-term results of a randomized study between laparoscopic and open surgery in elderly colorectal cancer patients. *Surgical Endoscopy.* 2014;28:466-476.

29. Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J. Long-term outcome of laparoscopic surgery for colorectal cancer: A cochrane systematic review of randomised controlled trials. *Cancer Treatment Reviews.* 2008;34(6):498-504.

30. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AMH, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *The Lancet.* 365(9472):1718-26.

31. Yamamoto S, Inomata M, Katayama H, Mizusawa J, Etoh T, Konishi F, et al. Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. *Ann Surg.* 2014;260(1):23-30.

32. Allaix ME, Giraudo G, Mistrangelo M, Arezzo A, Morino M. Laparoscopic versus open resection for colon cancer: 10-year outcomes of a prospective clinical trial. *Surgical Endoscopy.* 2015;29(4):916-24.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
33. Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM, Guillou PJ. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. *Br J Surg*. 2010;97(11):1638-45.
34. Martel G, Crawford A, Barkun JS, Boushey RP, Ramsay CR, Fergusson DA. Expert Opinion on Laparoscopic Surgery for Colorectal Cancer Parallels Evidence from a Cumulative Meta-Analysis of Randomized Controlled Trials. *PLoS ONE*. 2012;7(4):e35292.
35. Babaei M, Balavarca Y, Jansen L, Gondos A, Lemmens V, Sjøvall A, et al. Minimally Invasive Colorectal Cancer Surgery in Europe: Implementation and Outcomes. *Medicine*. 2016;95(22):e3812.
36. Ohtani H, Tamamori Y, Arimoto Y, Nishiguchi Y, Maeda K, Hirakawa K. A meta-analysis of the short- and long-term results of randomized controlled trials that compared laparoscopy-assisted and open colectomy for colon cancer. *J Cancer*. 2012;3:49-57.
37. Norwegian National guidelines on treatment of colorectal cancer. <http://www.helsedirektoratet.no/publikasjoner/>. 2015.
38. Stormark K, Søreide K, Søreide JA, Kvaløy JT, Pfeffer F, Eriksen MT, et al. Nationwide implementation of laparoscopic surgery for colon cancer: short-term outcomes and long-term survival in a population-based cohort. *Surgical Endoscopy*. 2016;30(11):4853-64.

Table 1: Distribution of annual resection volume per hospital unit and use of laparoscopy

Resections per year ¹	Hospital units (n)	Resections (n) ²	Laparoscopy (% (range)) ³
< 50	5	256	80 (62-100)
50-100	7	772	64 (41-100)
> 100	4	784	47 (28-80)
Total	16	1812	67 (28-100)

¹ Annual number of resections for colon cancer (source: Colorectal Cancer Registry of Norway, National report 2015, reference 3), ² Number of resections in the current cohort operated upon in a hospital unit within the corresponding volume group, ³ Percentage of resections in the current cohort performed with laparoscopy (ITT) within the corresponding volume group, with unit range in brackets.

Table 2: Univariable and multivariable analyses of association between the predictors and any major complication (Accordion score 3-6) within 30 days

		n	rate (%)	Univariable		Multivariable	
				OR (CI ¹)	p ²	adjusted OR (CI ¹)	p ³
All patients		1812	14,0				
Age group	<65	475	12,6	ref	0,049	-	-
	65-80	885	13,0	1,03 (0,74-1,43)			
	>80	452	17,5	1,46 (1,02-2,11)			
Gender	female	959	12,3	ref	0,026	-	-
	male	853	15,9	1,35 (1,04-1,76)			
WHO ECOG-score	0 or 1	1529	14,1	ref	0,058	-	-
	> 1	245	19,6	1,41 (0,99-2,02)			
mGPS	0	1080	13,7	ref	0,004	ref	0,022
	1	278	15,7	1,12 (0,77-1,64)		0,97 (0,66-1,42)	
	2	146	25,3	2,02 (1,32-3,09)		1,82 (1,17-2,82)	
ASA-score	I	121	6,6	ref	<0,001	ref	0,021
	II	994	12,8	1,94 (0,92-4,07)		1,50 (0,70-3,18)	
	III	650	19,5	3,17 (1,50-6,66)		2,27 (1,06-4,87)	
	IV	46	15,2	2,54 (0,86-7,45)		2,12 (0,68-6,44)	
Severe pulmonary disease	no	1681	13,7	ref	0,132	-	-
	yes	130	18,5	1,43 (0,90-2,27)			
Severe cardiac disease	no	1611	13,6	ref	0,134	-	-
	yes	200	17,5	1,35 (0,91-2,00)			
Weight class (BMI)	< 18,5	69	14,5	0,98 (0,48-1,97)	0,744	-	-
	18,5-25	683	15,8	ref			
	25-30	650	13,1	0,84 (0,62-1,15)			
	>30	283	15,9	0,98 (0,66-1,45)			
Access	Laparoscopy	1069	10,5	ref	<0,001	ref	0,004
	Open	743	19,1	2,02 (1,54-2,64)		1,55 (1,15-2,10)	
Resection type ⁴	IC and RHC	1032	13,5	ref	0,003	-	-
	SR	476	11,1	0,81 (0,58-1,13)			
	TRR and LHC	196	19,9	1,60 (1,08-2,37)			
	SC/TC and oth.	108	21,3	1,74 (1,06-2,85)			

¹ Values in parenthesis are 95 % confidence intervals. ² Chi-square tests. ³ Logistic regression analyses. ⁴ IC: ileocecal resection, RHC: right hemicolectomy, SR: sigmoid resection, TRR: transversal resection, LHC: left hemicolectomy, SC: subtotal colectomy, TC: total colectomy.

Table 3: Univariable and multivariable analyses of association between the predictors and reoperation of any cause within 30 days

		Univariable			Multivariable	
		rate (%)	OR (CI ¹)	p ²	adjusted OR (CI ¹)	p ³
All patients		8,7				
Age group	<65	8,2	ref	0,724	-	-
	65-80	9,3	1,10 (0,77-1,70)			
	>80	8,2	1,00 (0,62-1,59)			
Gender	female	7,4	ref	0,024	ref	0,020
	male	11,0	1,46 (1,05-2,03)			
WHO ECOG-score	0 or 1	9,0	ref	0,602	-	-
	> 1	10,0	0,88 (0,53-1,44)			
mGPS	0	9,0	ref	0,532	-	-
	1	6,8	0,77 (0,46-1,29)			
	2	10,3	1,11 (0,62-2,01)			
ASA-score	I	2,5	ref	0,086	-	-
	II	8,8	3,77 (1,18-12,18)			
	III	10,0	4,37 (1,35-14,14)			
	IV	6,5	2,74 (0,53-14,12)			
Severe pulmonary disease	no	8,7	ref	0,830	-	-
	yes	9,2	1,07 (0,58-1,98)			
Severe cardiac disease	no	8,6	ref	0,678	-	-
	yes	10,0	1,11 (0,67-1,84)			
Weight class (BMI)	< 18,5	7,2	0,84 (0,33-2,18)	0,840	-	-
	18,5-25	8,9	ref			
	25-30	8,5	0,98 (0,66-1,44)			
	>30	12,0	1,18 (0,74-1,90)			
Access	Laparoscopy	7,6	ref	0,039	-	-
	Open	10,4	1,41 (1,02-1,96)			
Resection type ⁴	IC and RHC	8,1	ref	0,003	ref	0,005
	SR	6,7	0,81 (0,53-1,24)			
	TRR + LHC	12,2	1,58 (0,97-2,55)			
	SC/TC and oth.	16,7	2,26 (1,30-3,92)			

¹ Values in parenthesis are 95 % confidence intervals. ² Chi-square tests. ³ Logistic regression analyses. ⁴ IC: ileocecal resection, RHC: right hemicolectomy, SR: sigmoid resection, TRR: transversal resection, LHC: left hemicolectomy, SC: subtotal colectomy, TC: total colectomy.

Table 4: Univariable and multivariable analyses of association between the predictors and reoperation for anastomotic leak (AL) within 30 days

		Anastomosis ¹ (%)	AL rate (%)	Univariable		Multivariable	
				OR (CI ²)	p ³	adjusted OR (CI ²)	p ⁴
All patients		91,8	3,8				
Age group	<65	91,8	4,6	ref	0,479	-	-
	65-80	92,1	3,4	0,74 (0,41-1,33)			
	>80	91,4	3,1	0,68 (0,33-1,38)			
Gender	female	91,7	3,0	ref	0,106	-	-
	male	92,0	4,5	1,53 (0,91-2,57)			
WHO ECOG-score	0 or 1	92,3	3,7	ref	0,999	-	-
	> 1	88,6	3,7	1,00 (0,47-2,14)			
mGPS	0	94,3	3,6	ref	0,940	-	-
	1	87,4	3,3	0,80 (0,42-1,97)			
	2	87,0	3,1	0,86 (0,30-2,46)			
ASA-score	I	91,7	1,8	ref	0,726	-	-
	II	93,6	3,8	2,13 (0,51-8,98)			
	III	89,8	4,1	2,34 (0,54-10,03)			
	IV	82,6	0	0			
Severe pulmonary disease	no	91,9	3,7	ref	0,854	-	-
	yes	91,5	3,4	0,91 (0,32-2,55)			
Severe cardiac disease	no	92,1	3,8	ref	0,287	-	-
	yes	89,5	2,2	0,57 (0,21-1,60)			
Weight class (BMI)	< 18,5	78,3	1,9	0,64 (0,08-4,91)	0,367	-	-
	18,5-25	92,4	2,9	ref			
	25-30	93,4	4,6	1,65 (0,90-3,01)			
	>30	92,6	3,8	1,35 (0,62-2,97)			
Access	Laparoscopy	95,0	3,3	ref	0,386	-	-
	Open	87,2	4,2	1,26 (0,75-2,10)			
Resection type ⁵	IC and RHC	96,6	2,8	ref	0,010	ref	0,010
	SR	88,4	3,6	1,28 (0,68-2,42)		1,28 (0,68-2,42)	
	TRR + LHC	92,3	6,6	2,46 (1,23-4,93)		2,46 (1,23-4,93)	
	SC/TC and oth.	60,2	9,2	3,52 (1,40-8,83)		3,52 (1,40-8,83)	

¹ Rate of patients who had a new anastomosis fashioned. ² Values in parenthesis are 95 % confidence intervals. ³ Chi-square tests. ⁴ Logistic regression analyses. ⁵ IC: ileocecal resection, RHC: right hemicolectomy, SR: sigmoid resection, TRR: transversal resection, LHC: left hemicolectomy, SC: subtotal colectomy, TC: total colectomy.

Table 5: Univariable and multivariable analyses of association between the predictors and mortality within 30 days

		Univariable			Multivariable	
		rate (%)	OR (CI ¹)	p ²	adjusted OR (CI ¹)	p ³
All patients		1,1	-		-	-
Age group	<65	0,8	ref	0,724	-	-
	65-80	0,7	0,80 (0,23-2,86)			
	>80	2,2	2,66 (0,83-8,56)			
Gender	female	1,3	ref	0,024	-	-
	male	0,9	0,75 (0,30-1,84)			
WHO ECOG-score	0 or 1	0,9	ref	0,602	-	-
	> 1	2,4	2,72 (1,03-7,14)			
mGPS	0	0,7	ref	0,532	-	-
	1	1,4	1,96 (0,59-6,55)			
	2	3,4	4,76 (1,54-14,74)			
ASA-score	I	0	I + II: ref III + IV: 9,28 (2,71-31,79)	0,086	-	-
	II	0,3				
	III	2,3				
	IV	4,3				
Severe pulmonary disease	no	0,8	ref	0,830	ref	0,002
	yes	5,4	7,31 (2,87-18,65)		4,95 (1,83-13,31)	
Severe cardiac disease	no	0,8	ref	0,678	ref	0,033
	yes	3,5	4,46 (1,76-11,32)		2,92 (1,09-7,82)	
Weight class (BMI)	< 18,5	0	0	0,840	-	-
	18,5-25	1,5	ref			
	25-30	0,8	0,52 (0,18-1,54)			
	>30	1,1	0,72 (0,20-2,64)			
Access	Laparoscopy	0,6	ref	0,039	ref	0,034
	Open	1,9	3,40 (1,30-8,90)		2,87 (1,08-7,59)	
Resection type ⁴	IC and RHC	1,2	ref	0,003	-	-
	SR	1,1	0,88 (0,20-3,95)			
	TRR + LHC	1,0	0,90 (0,32-2,58)			
	SC/TC and oth.	0,9	0,79 (0,10-6,17)			

¹ Values in parenthesis are 95 % confidence intervals. ² Chi-square tests. ³ Logistic regression analyses. ⁴ IC: ileocecal resection, RHC: right hemicolectomy, SR: sigmoid resection, TRR: transversal resection, LHC: left hemicolectomy, SC: subtotal colectomy, TC: total colectomy.

Table 6: Demographics of analyzed predictors stratified by access modality group

		Laparoscopy	Open	Comparison of access groups
		% of all laparoscopies	% of all open procedures	p ¹
Age group	<65	29,2	21,9	0,002
	65-80	46,2	52,6	
	>80	24,6	25,4	
Gender	female	51,6	54,8	0,188
	male	48,4	45,2	
WHO ECOG score	0 or 1	88,7	82,6	<0,001
	>1	11,3	17,4	
mGPS	0	77,8	63,6	<0,001
	1	13,9	24,8	
	2	8,3	11,7	
ASA score	I	8,7	3,8	<0,001
	II	56,3	52,9	
	III	33,1	39,8	
	IV	1,9	3,5	
Severe pulmonary disease	no	94,4	90,6	0,002
	yes	5,6	9,4	
Severe cardiac disease	no	90,4	86,9	0,022
	yes	9,6	13,1	
Weight class (BMI)	< 18,5	3,5	5,0	0,120
	18,5-25	40,9	40,0	
	25-30	40,0	36,4	
	>30	15,6	18,5	
Resection type ²	IC + RHC	56,7	57,3	<0,001
	SR	30,6	20,1	
	TRR + LHC	8,5	14,1	
	SC, TC and oth.	4,2	8,5	

¹ Chi-square tests. ² IC: ileocecal resection, RHC: right hemicolectomy, SR: sigmoid resection, TRR: transversal resection, LHC: left hemicolectomy, SC: subtotal colectomy, TC: total colectomy.

Table 7: Propensity score-adjusted odds and hazard ratios for access modality as predictor of outcomes

	Any major complication	Mortality	Length-of-stay
Open access (with laparoscopy as reference)	OR 1,67 (1,22-2,29) p = 0,002	OR 4,39 (1,19-16,13) p = 0,026	HR 0,58 (0,52-0,65) p <0,001

Numbers in parenthesis are 95% confidence intervals. Variables included when computing propensity score: Age, gender, WHO ECOG score, mGPS, ASA score, severe pulmonary and cardiac disease, weight group and resection type. Variables included in propensity score-corrected logistic regression analysis: propensity score, access modality, age and gender.


Figure legends

Figure 1: Flowchart for inclusion and categorization according to access modality for sub analyses

Figure 2: The distribution in severity of major postoperative complications presented as cumulative percentages of Accordion grade 3-6. In accordance with the Accordion system, only the highest graded complication is scored for any given patient journey. The cumulative percentages of Accordion score 3-6 are shown in the end of each column. Separate columns are given for the two access groups, and further stratified for age group with a cut-off of 80 years.

Figure 3: Crude incidences of all recorded reinterventions and organ failures within 30 days from index surgery. Notably, in contrast to the Accordion scale where only the most severe complication for each patient journey is graded (Figure 2), all events are here counted under the respective type of reintervention or organ failure group.

Figure 1: Flowchart for inclusion and categorization according to access modality for subanalyses



* defined by ICD-10 codes C18.0-9, C19, D01.0-1, D12.0-7, D37.2-4 or K63.5

** defined by start of anaesthesia between 4 PM and 8 AM or during weekends or public holidays




Figure 2: Distribution in Accordion score stratified by access modality group and age.




Figure 3: Crude incidences of reinterventions and organ failure stratified by access modality

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.